Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | -1.61% | -6.15% | -47.41% |
Sales 2024 * | 65.38M 5.23B | Sales 2025 * | 6.25M 500M | Capitalization | 20.32M 1.62B |
---|---|---|---|---|---|
Net income 2024 * | 24M 1.92B | Net income 2025 * | -41M -3.28B | EV / Sales 2024 * | 0.31 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.25 x |
P/E ratio 2024 * |
0.93
x | P/E ratio 2025 * |
-0.52
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.46% |
Latest transcript on MEI Pharma, Inc.
1 day | -1.61% | ||
1 week | -6.15% | ||
Current month | -23.75% | ||
1 month | -23.75% | ||
3 months | -32.97% | ||
6 months | -55.92% | ||
Current year | -47.41% |
Managers | Title | Age | Since |
---|---|---|---|
David Urso
CEO | Chief Executive Officer | 60 | 06/03/14 |
Justin File
DFI | Director of Finance/CFO | 53 | 11/06/23 |
Caroline Ruiz
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 25/02/18 |
Thomas Reynolds
BRD | Director/Board Member | 65 | 10/02/13 |
Charles Baltic
CHM | Chairman | 63 | 19/10/11 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.05 | -1.61% | 8,066 |
25/04/24 | 3.1 | -4.91% | 16,736 |
24/04/24 | 3.26 | -2.17% | 7,394 |
23/04/24 | 3.332 | -1.12% | 5,008 |
22/04/24 | 3.37 | +3.69% | 6,549 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.41% | 20.32M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MEIP Stock